Kiristioglu Mehmet Omer, Doganay Selim, Ucan Gunduz Gamze
Department of Ophthalmology, Bursa Uludag University School of Medicine, Bursa, 16059, Turkey.
BMC Ophthalmol. 2025 Jul 1;25(1):364. doi: 10.1186/s12886-025-04188-4.
To investigate axial length (AxL) variability and intraocular lens (IOL) power stability in macular edema (ME) patients undergoing intravitreal anti-VEGF therapy using Lenstar biometry.
In this preliminary observational study, 32 patients (64 eyes) with unilateral macular edema (ME) due to diabetic retinopathy or retinal vein occlusion were evaluated. AxL and IOL power were measured pre- and post-treatment using LenStar OLCR biometry. Three measurement strategies were employed: automated (AxLα), manually adjusted (AxLβ), and CRT-corrected (AxLγ). Four experienced ophthalmologists manually repositioned A-scan markers. Fellow eyes were assessed longitudinally. Statistical analyses included paired t-tests, intraclass correlation coefficients, and correlation tests.
The mean patient age was 61.38 ± 9.44 years. Anti-VEGF treatment significantly reduced mean CRT from 444.47 ± 121.16 μm to 374.50 ± 98.90 μm (p < 0.001). The mean preoperative and postoperative AxL were 23.11 ± 0.72 mm and 23.10 ± 0.72 mm, respectively (p = 0.091), showing no significant change. However, in cases with CRT > 300 μm, AxL reduction was statistically significant (p = 0.044), though IOL power calculations remained stable (p = 0.401). Interobserver agreement was high for AxL and IOL power measurements, with intraclass correlation coefficients of 0.854 preoperatively and 0.989 postoperatively. Manual adjustments resulted in significant AxL differences between pre- and post-treatment periods (p < 0.001), while automated Lenstar measurements remained consistent. Fellow eyes IOL and AxL remained identical in both preoperative and postoperative sessions (p = 0.323 for IOL and p = 0.287 for AxL).
This preliminary observational study suggests that AxL and IOL power measurements remain stable following anti-VEGF therapy in most ME cases. Small but consistent AxL changes in eyes with high CRT may indicate a structural threshold for biometric variability. OLCR-based biometry remains reliable in real-world practice.
使用Lenstar生物测量仪研究接受玻璃体内抗VEGF治疗的黄斑水肿(ME)患者的眼轴长度(AxL)变异性和人工晶状体(IOL)屈光力稳定性。
在这项初步观察性研究中,对32例因糖尿病视网膜病变或视网膜静脉阻塞导致单侧黄斑水肿(ME)的患者(64只眼)进行了评估。使用LenStar OLCR生物测量仪在治疗前后测量AxL和IOL屈光力。采用了三种测量策略:自动测量(AxLα)、手动调整测量(AxLβ)和CRT校正测量(AxLγ)。四位经验丰富的眼科医生手动重新定位A超标记。对健侧眼进行纵向评估。统计分析包括配对t检验、组内相关系数和相关性检验。
患者平均年龄为61.38±9.44岁。抗VEGF治疗使平均中心视网膜厚度(CRT)从444.47±121.16μm显著降低至374.50±98.90μm(p<0.001)。术前和术后平均AxL分别为23.11±0.72mm和23.10±0.72mm(p=0.091),无显著变化。然而,在CRT>300μm的病例中,AxL缩短具有统计学意义(p=0.044),尽管IOL屈光力计算保持稳定(p=0.401)。AxL和IOL屈光力测量的观察者间一致性较高,术前组内相关系数为0.854,术后为0.989。手动调整导致治疗前后AxL存在显著差异(p<0.001),而自动Lenstar测量结果保持一致。健侧眼的IOL和AxL在术前和术后检查中均保持相同(IOL的p=0.323,AxL的p=0.287)。
这项初步观察性研究表明,在大多数ME病例中,抗VEGF治疗后AxL和IOL屈光力测量保持稳定。CRT较高的眼中AxL虽有微小但一致的变化,这可能表明生物测量变异性的结构阈值。基于OLCR的生物测量在实际应用中仍然可靠。